<--- Back to Details
First PageDocument Content
Senescence / PARP inhibitor / PARP1 / DOTA-TATE / HeLa
Date: 2016-07-16 08:44:18
Senescence
PARP inhibitor
PARP1
DOTA-TATE
HeLa

Theranostics 2016, Vol. 6, IssueIvyspring

Add to Reading List

Source URL: www.thno.org

Download Document from Source Website

File Size: 2,43 MB

Share Document on Facebook

Similar Documents

Clinical medicine / Medicine / Health / Neuroendocrinology / Pancreatic cancer / Neuroendocrine tumor / Advanced Accelerator Applications / Pheochromocytoma / Paraganglioma / DOTA-TATE / Forward-looking statement / Endocrine oncology

PDF Document

DocID: 1qqKS - View Document

Senescence / PARP inhibitor / PARP1 / DOTA-TATE / HeLa

Theranostics 2016, Vol. 6, IssueIvyspring

DocID: 1q5FE - View Document

Peptides / DOTA-TATE / Radiopharmaceuticals / Pediatric cancers / Octreotide / Neuroendocrine tumor / Carcinoid / DOTA / Octreotate / Medicine / Chelating agents / Macrocycles

ENETS Guidelines Neuroendocrinology 2009;90:220–226 DOI: Received: August 27, 2008 Accepted after revision: January 27, 2009

DocID: 1avAb - View Document

Radiopharmaceuticals / DOTA-TATE / DOTA / Octreotate / Clinical Trials / Mallinckrodt Incorporated / Support / Alternative medicine / Chemistry / Chelating agents / Macrocycles

Microsoft Word - Mallinckrodt Dotatatedocx

DocID: 14wa8 - View Document

Radiobiology / Medical specialties / Chelating agents / Nuclear medicine / Radiation therapy / DOTA-TATE / Radiopharmacology / DOTA / Iodine-131 / Medicine / Radiation oncology / Radiopharmaceuticals

International Conference on Radiation Protection in Medicine Setting the Scene for the Next Decade Bonn, Germany, 3 - 7 December 2012 Radiation protection in radionuclide therapy in the next decade

DocID: VKQl - View Document